|
Nov 15
|
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcript
|
|
Nov 14
|
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
|
|
Nov 2
|
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
|
|
Apr 22
|
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
|